Egypt’s GYPTO Pharma, US Dawah sign strategic alliance to target US market

Egypt’s state-owned GYPTO Pharma signed on Tuesday a strategic alliance with US-based Dawah Pharmaceuticals as it seeks to upgrade local drug manufacturing capabilities and gain US Food and Drug Administration (FDA) certification. The move aimed at boosting Egypt’s pharmaceuticals exports to global markets.

The partnership will enable GYPTO Pharma to benefit from Dawah’s expertise in marketing and producing FDA-approved generics, including injectable and ophthalmic treatments. Dawah currently markets and manufacture a portfolio of FDA-approved medicines, medicines in the US, according to its website.

Egyptian Prime Minister Moustafa Madbouly said the alliance will bring advanced American technology and regulatory know-how to Egypt’s pharmaceutical sector, positioning it for global competition, according to a statement from Egypt’s Cabinet.  The deal aligns with President Abdel Fattah El-Sisi’s push to expand Egypt’s industrial base and increase high-value exports.

The collaboration is expected to drive bilateral trade and investment in biopharmaceuticals, while also improving production efficiency and product quality for consumers in both Egypt and the US, the statement said.

GYPTO Pharma is part of Egypt’s strategy to become a regional hub for drug manufacturing, with a focus on meeting international standards to tap new export markets.

Attribution: Amwal Al Ghad English

Subediting: Y.Yasser